Alnylam Pharmaceuticals Inc. Daily Stock Analysis

Daily Stock Analysis, ALNY, Alnylam Pharmaceuticals Inc, priceseries

Alnylam Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
163.75
Close
163.00
High
165.21
Low
161.91
Previous Close
164.44
Daily Price Gain
-1.44
YTD High
174.66
YTD High Date
Jan 4, 2022
YTD Low
125.00
YTD Low Date
Jan 28, 2022
YTD Price Change
-10.91
YTD Gain
-6.27%
52 Week High
212.00
52 Week High Date
Oct 14, 2021
52 Week Low
125.00
52 Week Low Date
Jan 28, 2022
52 Week Price Change
24.38
52 Week Gain
17.59%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 24. 2017
46.62
Mar 13. 2017
50.52
11 Trading Days
8.37%
Link
LONG
May 12. 2017
56.77
May 26. 2017
67.35
10 Trading Days
18.64%
Link
LONG
Jun 1. 2017
69.70
Jun 27. 2017
80.59
18 Trading Days
15.62%
Link
LONG
Mar 7. 2018
123.99
Mar 23. 2018
139.26
12 Trading Days
12.31%
Link
LONG
Nov 23. 2018
73.34
Dec 4. 2018
78.61
7 Trading Days
7.19%
Link
LONG
Dec 28. 2018
70.40
Jan 15. 2019
79.96
11 Trading Days
13.58%
Link
LONG
Oct 11. 2019
78.97
Oct 30. 2019
87.28
13 Trading Days
10.52%
Link
LONG
Nov 15. 2019
92.05
Dec 11. 2019
119.42
17 Trading Days
29.73%
Link
LONG
Apr 8. 2020
111.39
Apr 29. 2020
133.27
14 Trading Days
19.64%
Link
LONG
Jun 16. 2020
132.26
Jul 13. 2020
155.29
18 Trading Days
17.42%
Link
LONG
Jan 7. 2021
139.40
Jan 27. 2021
163.62
13 Trading Days
17.37%
Link
LONG
Jun 7. 2021
150.46
Jun 28. 2021
167.75
15 Trading Days
11.49%
Link
LONG
Aug 4. 2021
183.44
Aug 31. 2021
201.44
19 Trading Days
9.81%
Link
LONG
Sep 30. 2021
188.81
Oct 20. 2021
203.98
14 Trading Days
8.03%
Link
LONG
Jan 31. 2022
137.60
Feb 18. 2022
146.49
14 Trading Days
6.46%
Link
Company Information
Stock Symbol
ALNY
Exchange
NasdaqGS
Company URL
http://www.alnylam.com
Company Phone
(617) 551-8200
CEO
John M. Maraganore
Headquarters
Massachusetts
Business Address
300 THIRD STREET, CAMBRIDGE, MA 02142
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001178670
About

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Description

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference. Its pipeline of investigational RNAi therapeutics is focused on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of transthyretin-mediated amyloidosis (ATTR); Fitusiran, an investigational RNAi therapeutic that is in Phase I/II clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran (ALN-PCSsc), which is in Phase II clinical trial for hypercholesterolemia. Its early stage clinical programs include Givosiran that is in Phase I trial to treat acute hepatic porphyrias; ALN-CC5 for the treatment of complement-mediated diseases; ALN-GO1 to treat primary hyperoxaluria 1; ALN-TTRsc02, an investigational RNAi therapeutic targeting TTR for the treatment of various forms of ATTR amyloidosis; and ALN-HBV for the treatment of Hepatitis B virus. The company has strategic alliances and collaboration agreements primarily with Sanofi Genzyme; The Medicines Company; Monsanto Company; Takeda Pharmaceutical Company Limited; Ionis Pharmaceuticals, Inc.; The University of British Columbia; and Acuitas Therapeutics Inc.; and Arbutus Biopharma Corporation. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading